La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
AC Immune Gestion
Gestion contrôle des critères 3/4
AC Immune's CEO is Andrea Pfeifer, appointed in Apr 2003, has a tenure of 21.33 years. total yearly compensation is CHF2.65M, comprised of 21.8% salary and 78.2% bonuses, including company stock and options. directly owns 2.45% of the company’s shares, worth $8.16M. The average tenure of the management team and the board of directors is 3.9 years and 6.3 years respectively.
Informations clés
Andrea Pfeifer
Directeur général
CHF 2.7m
Rémunération totale
Pourcentage du salaire du PDG | 21.8% |
Durée du mandat du directeur général | 21.3yrs |
Propriété du PDG | 2.4% |
Durée moyenne d'occupation des postes de direction | 3.9yrs |
Durée moyenne du mandat des membres du conseil d'administration | 6.3yrs |
Mises à jour récentes de la gestion
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -CHF 61m |
Mar 31 2024 | n/a | n/a | -CHF 55m |
Dec 31 2023 | CHF 3m | CHF 578k | -CHF 54m |
Sep 30 2023 | n/a | n/a | -CHF 68m |
Jun 30 2023 | n/a | n/a | -CHF 67m |
Mar 31 2023 | n/a | n/a | -CHF 69m |
Dec 31 2022 | CHF 2m | CHF 558k | -CHF 71m |
Sep 30 2022 | n/a | n/a | -CHF 73m |
Jun 30 2022 | n/a | n/a | -CHF 76m |
Mar 31 2022 | n/a | n/a | -CHF 75m |
Dec 31 2021 | CHF 2m | CHF 530k | -CHF 73m |
Sep 30 2021 | n/a | n/a | -CHF 71m |
Jun 30 2021 | n/a | n/a | -CHF 74m |
Mar 31 2021 | n/a | n/a | -CHF 71m |
Dec 31 2020 | CHF 2m | CHF 520k | -CHF 62m |
Sep 30 2020 | n/a | n/a | -CHF 62m |
Jun 30 2020 | n/a | n/a | -CHF 25m |
Mar 31 2020 | n/a | n/a | -CHF 26m |
Dec 31 2019 | CHF 2m | CHF 510k | CHF 45m |
Sep 30 2019 | n/a | n/a | CHF 50m |
Jun 30 2019 | n/a | n/a | CHF 18m |
Mar 31 2019 | n/a | n/a | CHF 24m |
Dec 31 2018 | CHF 2m | CHF 455k | -CHF 51m |
Sep 30 2018 | n/a | n/a | -CHF 32m |
Jun 30 2018 | n/a | n/a | -CHF 27m |
Mar 31 2018 | n/a | n/a | -CHF 29m |
Dec 31 2017 | CHF 2m | CHF 404k | -CHF 26m |
Rémunération vs marché: Andrea's total compensation ($USD3.07M) is about average for companies of similar size in the US market ($USD2.44M).
Rémunération et revenus: Andrea's compensation has increased whilst the company is unprofitable.
PDG
Andrea Pfeifer (67 yo)
21.3yrs
Titularisation
CHF 2,650,000
Compensation
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Co-Founder | 21.3yrs | CHF 2.65m | 2.45% CHF 8.2m | |
CFO & VP of Finance | 2.3yrs | pas de données | 0.013% CHF 42.5k | |
Chief Technical Operations Officer | 5.5yrs | pas de données | 0.025% CHF 82.6k | |
Chief Administrative Officer | 9.1yrs | pas de données | 0.32% CHF 1.1m | |
Chief HR Officer | 2.3yrs | pas de données | 0.020% CHF 67.9k | |
Chief Medical Officer | less than a year | pas de données | 0.0083% CHF 27.7k | |
Chief Scientific Officer | less than a year | pas de données | 0.0032% CHF 10.7k | |
Senior VP of Investor Relations & Corporate Communications | no data | pas de données | pas de données | |
General Counsel | no data | pas de données | pas de données | |
VP of U.S. Finance & Corporate Development | 2.3yrs | pas de données | pas de données | |
Head of AD - SME | 14.6yrs | pas de données | pas de données | |
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer | 8.5yrs | pas de données | pas de données |
3.9yrs
Durée moyenne de l'emploi
53yo
Âge moyen
Gestion expérimentée: ACIU's management team is considered experienced (3.9 years average tenure).
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Co-Founder | 8.3yrs | CHF 2.65m | 2.45% CHF 8.2m | |
Chairman of Scientific Advisory Board | no data | pas de données | pas de données | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Independent Non-Executive Chairman | 6.3yrs | CHF 179.00k | 0.039% CHF 131.2k | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Member of Scientific Advisory Board | no data | CHF 5.00k | pas de données | |
Member of Scientific Advisory Board | no data | CHF 105.00k | pas de données | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Member of Scientific Advisory Board | no data | pas de données | pas de données | |
Independent Vice Chair | 2.8yrs | CHF 163.00k | 0.0092% CHF 30.8k | |
Head of Clinical Advisory Board | no data | pas de données | pas de données |
6.3yrs
Durée moyenne de l'emploi
74.5yo
Âge moyen
Conseil d'administration expérimenté: ACIU's board of directors are considered experienced (6.3 years average tenure).